Stopping semaglutide before abdominoplasty

As prescriptions for semaglutide continue to grow, plastic surgeons are encountering a practical question: how long before an elective procedure should a patient stop the drug? A retrospective study published in Aesthetic Plastic Surgery in June 2026 offers the first head-to-head comparison of different discontinuation windows in patients undergoing aesthetic abdominoplasty^[1].

The study design

Bruno, Calicchia, and Schirosi reviewed 80 patients who underwent primary lipoabdominoplasty at a single centre. The patients were divided into four groups matched for age, BMI, and surgical technique^[1]:

Group A continued semaglutide through surgery. Group B discontinued two weeks before the procedure. Group C discontinued four weeks before. Group D had never taken semaglutide and served as the control^[1].

Complication rates by group

The 30-day postoperative complication rates showed a clear gradient. Group A (no discontinuation) had a 45% complication rate. Group B (two-week washout) came in at 30%. Group C (four-week washout) matched the semaglutide-naive controls in Group D, both at 10%^[1].

Complications tracked included wound dehiscence, infection, seroma formation, gastrointestinal intolerance, and prolonged drain duration. No reoperations or hospital readmissions were documented in any group^[1].

Why the washout period matters

Semaglutide has an elimination half-life of approximately one week, meaning it takes roughly five weeks after the last dose for the drug to clear the body^[3]. The Wegovy prescribing information states that semaglutide delays gastric emptying, is not recommended in patients with severe gastroparesis, and notes rare postmarketing reports of pulmonary aspiration in patients on GLP-1 receptor agonists undergoing elective surgery who had residual gastric contents despite fasting^[3].

The four-week washout in Group C would have cleared roughly four half-lives, reducing circulating semaglutide to about 6% of steady-state levels. The two-week washout in Group B would have cleared only about two half-lives, leaving roughly 25% of the drug in circulation. The complication data from this study align with that pharmacokinetic logic.

This pharmacokinetic profile is shared by other long-acting GLP-1 receptor agonists. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has a similarly long half-life of about five days and would present comparable perioperative considerations. The broader point is that weekly injectables in this class need more lead time before elective procedures than most patients or surgeons might assume.

How this fits with existing guidance

The American Society of Anesthesiologists published consensus guidance in 2024 recommending that clinicians consider holding GLP-1 receptor agonists before elective surgery, citing concerns about delayed gastric emptying and aspiration risk under anaesthesia^[2]. That guidance focused primarily on the anaesthesia risk rather than wound healing or surgical complications, and it left the specific discontinuation interval somewhat open-ended.

This abdominoplasty study adds a different angle. The complications it measured, including wound dehiscence, seroma, and infection, are surgical rather than anaesthetic. The finding that four weeks was sufficient to normalise those outcomes gives surgeons a more concrete target to discuss with patients, though the authors note the sample size is small and the design is retrospective.

Related findings in aesthetic surgery

The same lead author published a separate prospective study in April 2026 measuring thromboinflammatory markers in 60 abdominoplasty patients. That study found that patients who had been on GLP-1 receptor agonists preoperatively showed lower perioperative inflammatory responses (CRP, IL-6, fibrinogen) compared to controls who achieved equivalent weight loss through lifestyle changes alone^[4]. No symptomatic venous thromboembolism occurred in the GLP-1 group, compared with two cases in the control group^[4].

A separate 2025 prospective cohort study by Albanese and colleagues compared 21 semaglutide-treated patients against controls undergoing 360-degree lipoabdominoplasty and found no statistically significant difference in major complications, though bruising and hyperpigmentation trended higher in the GLP-1 group^[5].

The broader perioperative question

This study sits within a wider conversation about GLP-1 receptor agonists and surgical safety. As millions of patients now take these drugs for weight management and type-2 diabetes, every surgical specialty is having to adapt perioperative protocols. The challenge is that the evidence base is still thin. Most of the available data come from case reports, small retrospective series, and consensus statements rather than large randomised trials.

For plastic surgery specifically, the intersection is particularly relevant because many patients seek body contouring procedures after substantial GLP-1-assisted weight loss. The question is not only when to stop the drug before surgery, but also when the patient has reached a stable enough weight plateau for the procedure to make sense. Rapid ongoing weight loss at the time of surgery can complicate outcomes independently of the drug itself.

Surgeons considering these patients also need to account for nutritional status. Prolonged GLP-1 receptor agonist use can reduce caloric intake substantially, and micronutrient deficiencies in protein, iron, and B vitamins have been reported in patients on long-term therapy. Albumin and prealbumin levels, markers of protein status relevant to wound healing, merit assessment in the preoperative workup^[5].

Limitations worth noting

This is a single-centre retrospective study with 20 patients per group. It was not randomised, and there is no blinding. The complication rate differences are large enough to be clinically interesting, but the sample is too small for definitive conclusions. The study does not report on anaesthetic complications, aspiration events, or long-term outcomes beyond 30 days.

The authors recommend a four-week preoperative discontinuation period for semaglutide before aesthetic abdominoplasty^[1]. That recommendation is consistent with the drug's pharmacokinetics and with the general direction of the ASA guidance, but it has not yet been validated in a prospective randomised trial.

This article is for informational purposes only and does not constitute medical advice. Decisions about when to discontinue any medication before surgery should be made in consultation with your surgeon and prescribing clinician.